Phase II/III clinical trial - Gynécologie

Ouvert depuis le: 12.08.2021
Site: Paris
Public cible
A multicentric randomized phase II/III evaluating TSR-042 (anti-PD-1 mAb) in combination with Niraparib (parpi) versus Niraparib alone compared to chemotherapy in the treatment of metastatic or recurrent endometrial or ovarian carcinosarcoma after at least one line of chemotherapy
Description de l'essai

Niraparib is an orally available, potent, highly selective poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) -1 and -2 inhibitor.;TSR-042 (Dostarlimab) is a humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities.;The chemotherapy consists of Paclitaxel/PLD/Topotecan for patients with ovarian cancer and Doxorubicin/Paclitaxel/Gemcitabine for patients with endometrial cancer.